Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions and methods of live attenuated alphavirus formulations

A composition and alpha virus technology, applied in biochemical equipment and methods, antiviral agents, viruses, etc., can solve problems such as vaccine inactivation, temperature limit sensitivity, etc.

Inactive Publication Date: 2020-07-17
TAKEDA VACCINES INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Other commonly used vaccines are sensitive to temperature extremes; overheating or accidental freezing can inactivate the vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods of live attenuated alphavirus formulations
  • Compositions and methods of live attenuated alphavirus formulations
  • Compositions and methods of live attenuated alphavirus formulations

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0101] Buffer screening

[0102] In certain exemplary methods, liquid and lyophilizable compositions suitable for use in preclinical and clinical trials and alphavirus vaccines are identified. One consideration with regard to liquid compositions according to these exemplary compositions is that some alphaviruses are pH sensitive (eg sensitive to low pH). Accordingly, the components of the compositions disclosed herein include a carefully considered pH factor. In certain exemplary compositions, the pH of the formulation is from about pH 6 to about 10, with many formulations having a pH of about pH 6.5-7.5 and up to about 9.5.

[0103] In some approaches, attenuated Chikungunya virus (hereinafter CHIK) is used as an example of an alphavirus composition in preclinical and clinical trials.

[0104] Compositions for use in these methods are provided. In an exemplary experiment, predetermined amounts of CHIK-IRES vaccine (pMVS), where the attenuated virus is controlled by IRES in...

Embodiment 2

[0108] In some other exemplary approaches, based on the observation that inclusion of one or more carbohydrates has a positive effect on CHIK vaccine stability, long-term stability experiments at 4°C were performed to analyze the effect of different carbohydrates (e.g., sugars) on alphaviruses. Effects on Stability of Vaccines (eg CHIK Virus Vaccine). Compositions containing HEPES and carbohydrates such as sucrose, lactose, trehalose, galactose, fructose, D-sorbitol, dextrose and D-mannitol) are produced. Aliquots of predetermined concentrations of CHIK-IRES vaccine (pMVS) were formulated in these compositions and incubated at 4°C for 12 weeks. exist figure 2 Samples were collected and titrated to Vero cells at the time points indicated. Such as figure 2 It was shown that the composition of about 15% trehalose, 15% sucrose or 10% D-mannitol combined with HEPES buffered saline (HB) showed about the same effect on virus stability as other compositions, better than other com...

Embodiment 3

[0112] Screening of formulations for protein-induced stability

[0113] In other exemplary methods, different protein agents are assayed for increasing the stability of alphavirus formulations compared to controls (no protein or with unfavorable other proteins). Compositions containing HB or HBS and the protein agent of interest were analyzed. In each experimental condition about 10 5 After incubation (~21 hours at 37°C) of the attenuated CHIK vaccine composition, an aliquot was taken and passed through TCID 50 Growth in Vero cells was titrated. Then, evaluate the percentage of remaining virus titer. Such as Figure 4 Addition of gelatin to formulations with or without carbohydrates increases the stability of alphavirus vaccines at 37°C as shown in (see Figure 4 ).

[0114] Figure 4 Shows exemplary total percentages of CHIK virus titers remaining after ~21 hours of incubation in a composition containing HEPES-buffered saline and proteins such as lactoferrin, tryptone,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Embodiments of the present application relate to compositions of and methods for attenuating live alphaviruses. In certain embodiments, live attenuated virus compositions include, but are not limited to, one or more live attenuated alphaviruses and compositions that reduce inactivation and / or degradation of live attenuated alphaviruses. In other embodiments, the live attenuated virus composition may be a vaccine composition. While in other compositions, the live attenuated alphavirus composition may comprise a HEPES buffer. In other embodiments, the HEPES buffer may also comprise carbohydrates and gelatin and / or salts.

Description

[0001] priority [0002] This PCT application claims priority to US Provisional Application No. 61 / 784,122, filed March 14, 2013. This provisional application is hereby incorporated by reference in its entirety for all purposes. [0003] field of invention [0004] Embodiments herein relate to compositions and methods for stabilizing live attenuated viruses. Other embodiments relate to compositions and methods for reducing degradation of live attenuated viruses. Other embodiments relate to the use of these compositions in kits for portable administration and methods. [0005] Background of the invention [0006] Vaccines that protect against viral infection have been used effectively to reduce the incidence of disease in humans or animals. One of the most successful techniques for viral vaccines is to immunize animals or humans with a weakened or attenuated strain of the virus ("live attenuated virus"). Attenuated strains do not cause disease due to limited replication aft...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/12
CPCC12N2770/36134A61K2039/5254A61K39/12A61P31/12A61P31/14A61P37/04Y02A50/30A61K47/22A61K47/26A61K47/42
Inventor 丹·T·斯廷奇科姆吉尔·A·利文格德拉兹洛·瓦尔加
Owner TAKEDA VACCINES INC